The impact of highly active antiretroviral therapy on the survival of vertically HIV-infected children and adolescents in Belo Horizonte, Brazil

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 4, 2012, Pages 532-538

  Cardoso, Claudete Aparecida Araújo ^a   Pinto, Jorge A ^a   Candiani, Talitah Michel Sanchez ^a   de Carvalho, Inácio Roberto ^a   Linhares, Renato Moreira ^a   Goulart, Eugênio Marcos Andrade ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Children and adolescents; HAART; Historic cohort; HIV; Survival

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CHILD; COHORT ANALYSIS; DISEASE TRANSMISSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; MORTALITY; NEWBORN; PRESCHOOL CHILD; RISK FACTOR; STATISTICS; SURVIVAL; VERTICAL TRANSMISSION; VIRUS LOAD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; RISK FACTORS; SURVIVAL ANALYSIS; VIRAL LOAD; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84862273704     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000400014     Document Type: Article

References (41)

1. Blanche S, Tardieu M, Duliège AM, Rouzioux C, Le Deist F, Fukunaga K, Caniglia M, Jacomet C, Messiah A, Griscelli C 1990. Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection: evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child 144: 1210-1215.
2. Brettler DB, Forsberg A, Bolivar E, Brewster F, Sullivan J 1990. Growth failure as a prognostic indicator for progression to ac-quired immunodeficiency syndrome in children with hemophilia. J Pediatr 117: 584-588.
3. Candiani TMS, Pinto JA, Cardoso CAA, Carvalho IR, Dias ACM, Carneiro M, Goulart EA 2007. Impact of highly active antiret-roviral therapy (HAART) on the incidence of opportunistic in-fections, hospitalizations and mortality among children and ado-lescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica 23 (Suppl. 3): S414-S423.
4. CDC Centers for Disease Control and Prevention 1994. 1994 revised classification system for human immunodeficiency virus (HIV) infection in children less than 13 years of age. MMWR 43: 1-10.
5. De Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P, Italian Register for HIV Infection in children and the Italian National AIDS Register 2000. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 284: 190-197.
6. ECS-European Collaborative Study 1994. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pedi-atrics 94: 815-819.
7. ECS-European Collaborative Study 2006. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis 193: 954-962.
8. Essajee S, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, Hoover W, Lawrence R, Spiegel H, Pollack H, Krasinski K, Borkowsky W 1999. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1 infected children. AIDS 13: 2323-2332.
9. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, Blanche S, Msellati P 2004. Highly active antiretroviral ther-apy among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS 18: 1905-1913.
10. Frederick T, Thomas P, Mascola L, Hsu Ho-Wen, Rakusan T, Mapson C, Weedon J, Bertolli J 2000. Human immunodeficiency virus-infected adolescents: a descriptive study of older children in New York city, Los Angeles County, Massachusetts and Washington, DC. Pediatr Infect Dis J 19: 551-555.
11. Gibb DM, Duong T, Tookey, TudorWilliams G, Novelli V, Bultler K, Riordan A, Farrelly L, Masters J, Peckham CS, Dunn DT, National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study 2003. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 327: 1019-1023.
12. Goethebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, Green H, Galli L, Ramos JT, Giaquinto C, Warszawski J, Levy J, European Infant Collaboration group 2009. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 23: 597-604.
13. Gona P, van Dyke R, Williams PL, Dankner WM, Chernof ML, Nachman SA, Seage GR 2006. Incidence of opportunistic and others infections in HIV-infected children in the HAART era. JAMA 296: 292-300.
14. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, Song LY, Dankner WM, Oleske JM, for The Pediatric AIDS Clinical Trial Group 219 team 2001. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 345: 1522-1528.
15. Granados JMS, Amador JTR, Miguel SF, Tomé MIG, Conejo PR, Vivas PF 2003. Impact of highly antiretroviral therapy on the mor-bidity and mortality in Spanish human immunodeficiency virus infected children. Pediatr Infect Dis J 22: 863-867.
16. IRHIC-Italian Register for HIV Infection in Children 1994. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet 343: 191-195.
17. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, Novelli V, Lyall EG, Masters J, Tudor-Williams G, Duong T, Gibb DM, Collaborative HIV Paediatric Study (CHIPS), National Study of HIV in Pregnancy and Childhood (NSHPC) 2007. Morbidity, mortality and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 45: 918-924.
18. Kapogiannis BG, Soe MM, Nesheim SR, Abrams EJ, Carter RJ, Farley J, Palumbo P, Koenig LJ, Bulterys M 2011. Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Clin Infect Dis 53: 1024-1034.
19. Kline MW, Matusa RF, Copaciu L, Calles NR, Kline NE, Schwarzwald HL 2004. Comprehensive pediatric human immunodefi-ciency virus care and treatment in Constanta, Romania. Implementation of a Program of highly active antiretroviral therapy in a resource-poor setting. Pediatr Infect Dis J 23: 695-700.
20. Kline MW, Paul ME, Bohannon B, Kozinetz CA, Shearer WT 1995. Characteristics of children surviving to 5 years of age or older with vertically acquired HIV infection. Pediatr AIDS HIV Infect Fetus Adolesc 6: 350-353.
21. Marins JRP, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, Chequer P, Teixeira PR, Hearst N 2003. Dramatic improve-ment in survival among adult Brazilian AIDS patients. AIDS 17: 1675-1682.
22. Matida LH, Marcopito LF, Grupo Brasileiro de Estudo da Sobrevida em Crianças com AIDS 2002. Aumento do tempo de sobrevida das crianças com aids Brasil. Coordenação Nacional de DST-AIDS. Boletim Epidemiológico 4. [accessed on September 13, 2011]. Available from: aids.gov.br/data/documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36 1903553A3174%7D/%7B3C849B6E-AF5E-48DE-9DC1 2AC2DBED6873%7D/bol_marco_2002.pdf.
23. Matida LH, Silva MH, Tayra A, Succi RCM, Gianna MC, Gonçalves A, de Carvalho HB, Hearst N 2005. Prevention of mother-to-child transmission of HIV in São Paulo state, Brazil: an update. AIDS 19 (Suppl. 4): S37-S41.
24. McConnel MS, Byers RH, Frederick T, Peters VB, Dominguez KL, Sukalac T, Greenberg AE, Hsu HW, Rakusan TA, Ortiz IR, Melville SK, Fowler MG, Pediatric Spectrum of HIV Disease Consortium 2005. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquired Immune Defic Syndr 38: 488-494.
25. Mocroft MA, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lund-gren JD 1998. Changing patterns of mortality accross Europe in patients infected with HIV-1. Lancet 352: 1725-1730.
26. Mofenson LM, Korelitz J, Meyer WA, Bethel J, Rich K, Pahwa S, Moye J Jr, Nugent R, Read J 1997. The relationship between se-rum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent and long-term mortality risk in HIV-1infected children. Journal Infect Dis 175: 1029-1038.
27. MS-Ministério da Saúde 2004. Secretaria de Vigilância em Saúde. Programa Nacional de DST e AIDS. Critérios de definição de ca-sos de AIDS em adultos e crianças. [accessed on September 13, 2011]. Available from: saude.rj.gov.br/Docs/Dstaids/criterios.pdf.
28. MS-Ministério da Saúde 2009. Secretaria de vigilância em saúde. Programa Nacional de DST e Aids. Guia de tratamento clinic da infecção pelo HIV em crianças. Programa Nacional de DST e Aids. [accessed on September 13, 2011]. Available from: aids. gov.br/sites/default/files/consenso_pediatrico.pdf.
29. MS-Ministério da Saúde 2010. Programa Nacional de DST e AIDS. Boletim Epidemiológico 1. [accessed on September 13, 2011]. Available from aids.gov.br/sites/default/files/anexos/publicacao/2010/45974/boletim_2010_pdf_14544.pdf.
30. Peacock-Villada E, Richardson BA, John-Stewart GC 2011. Post HAART outcomes in pediatric populations: comparison of re-source-limited and developed countries. Pediatrics 127: 423-441.
31. Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, Rouzioux C, Blanche S, Msellati P 2006. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 20: 2315-2319.
32. Scott GB, Hutto C, Makuck RW, Mastrucci MT, O'Connor T, Mitcheli CD, Trapido EJ, Parks WP 1989. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 321: 1971-1976.
33. Selik RM, Lindegren ML 2003. Changes in deaths reported with human immunodeficiency virus infection among United States children less than 13 years old, 1987 through 1999. Pediatr Infect Dis J 22: 635-641.
34. Teglas J, Mayaux M, Blanche S 2000. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA 284: 2871-2872.
35. Tovo P, Gabiano C, Palomba E, De Martino M, Galli L, Cappello N, D'Elia R, Loy A, Plebani A, Zuccotti GV, Dallacasa P, Ferraris G 1992. Prognostic factors and survival in children with perinatal HIV-1 infection. Lancet 339: 1249-1253.
36. UNAIDS Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization 2010. AIDS Epidemic Update 2010. [accessed on September 13, 2011]. Available from unaids.org/documents/20101123_GlobalReport_Chap2_em.pdf.
37. USWGARV-The Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children 2011. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. [accessed on September 13, 2011]. Available from: AIDSinfo.nih.gov/guidelines/.
38. van Rossum AM, Geelen S, Hartwing N, Wolfs TFW, Weemaes CMR, Scherpbier HJ, van Lochem EG, Hop WC, Schutten M, Osterhaus AD, Burger DM, de Groot R 2002. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 34: 1008-1016.
39. van Rossum AM, Scherpbier HJ, van Lochem EG, Pakker NG, Slieker WAT, Wolthers KC, Roos MT, Kuijpers JH, Hooijkaas H, Hartwig NG, Geelen SP, Wolfs TF, Lange JM, Miedema F, de Groot R, Dutch Study Group for Children with HIV Infections 2001. Therapeutic immune reconstitution in HIV-1 infected children is independent of their age and pre treatment immune status. AIDS 15: 2267-2275.
40. Verweel G, van Rossum AM, Hartwing NG, Wolfs TF, Scherpbier HJ, de Groot R 2002. Treatment with highly active antiretroviral treatment in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 109: e25.
41. Violari A, Paed FC, Cotton MF, Med M, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA, for the CHER Study Team 2008. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359: 2233-2244.